Hepcludex FDA Approval: What Bulevirtide Changes for Chronic Hepatitis D
FDA approval gives chronic hepatitis D a US treatment pathway. The harder question is whether evidence, diagnosis, price and payer access can catch up.
Read the briefing →Frontier 05 / Biotech
Biotech is where biology becomes programmable.
Vastkind follows tools, platforms, labs, data, and companies turning biology into a design, measurement, and production problem.
Programmable biology
Labs
Translation
Current signal
Latest ↓
Read now
Latest Biotech signals.
Newest biotech stories on tools, platforms, translation, and proof.
Global Cancer Workforce Crisis: Why Better Treatments Still Need a Capacity Stack
A Lancet Oncology Commission turns cancer care into an infrastructure story: survival depends on people, diagnostics, equipment, and capacity.
Brain-Computer Interfaces Are Becoming a Human Interface Problem
Brain-computer interfaces are no longer only a lab miracle. They are becoming a new human interface layer, and that changes the stakes.
Personalized CRISPR Needs a Platform
The miracle case is not enough. Personalized CRISPR now has to become medicine that can scale.
IVF Is Becoming More Automated. The Hard Question Is What Reproduction Becomes Next.
IVF is becoming more automated and data-driven, but the future of fertility will be shaped as much by access, ethics, and trust as by lab performance.
Prime Editing in Humans: First Proof, Big Questions Ahead
Prime editing has crossed from elegant theory into the clinic, but the hardest questions are still ahead.
Medical Microrobots Will Win by Choosing the Right Jobs First
The real microrobotics story is not tiny robots conquering the bloodstream. It is the discovery that narrow, controllable clinical environments can make the field finally useful.
Field note
Read the board before it turns into noise.
A compact operating note for Biotech: what changed, what to watch, what to doubt, and where the constraint sits.
Biology joins the automation stack
Discovery is becoming more computational, measured, and workflow-driven.
Closed-loop labs
Systems that design, run, measure, and revise experiments faster.
Biology is just software now.
AI can replace experiments.
Biological complexity
Living systems often refuse simple engineering assumptions.
Corridors
Routes around Biotech.
Use these routes when a story crosses into neighboring fields, forces, or reading formats.
Latest corridor story
Hepcludex FDA Approval: What Bulevirtide Changes for Chronic Hepatitis D
Latest corridor story
Personalized CRISPR Needs a Platform
Archive
All Biotech stories, compact.
Use the archive for retrieval; the map above carries the orientation.
Global Cancer Workforce Crisis: Why Better Treatments Still Need a Capacity Stack
A Lancet Oncology Commission turns cancer care into an infrastructure story: survival depends on people, diagnostics, equipment, and capacity.
Brain-Computer Interfaces Are Becoming a Human Interface Problem
Brain-computer interfaces are no longer only a lab miracle. They are becoming a new human interface layer, and that changes the stakes.
Personalized CRISPR Needs a Platform
The miracle case is not enough. Personalized CRISPR now has to become medicine that can scale.
IVF Is Becoming More Automated. The Hard Question Is What Reproduction Becomes Next.
IVF is becoming more automated and data-driven, but the future of fertility will be shaped as much by access, ethics, and trust as by lab performance.
Prime Editing in Humans: First Proof, Big Questions Ahead
Prime editing has crossed from elegant theory into the clinic, but the hardest questions are still ahead.
Medical Microrobots Will Win by Choosing the Right Jobs First
The real microrobotics story is not tiny robots conquering the bloodstream. It is the discovery that narrow, controllable clinical environments can make the field finally useful.
Biotech’s Real Frontier Is Not Hype. It Is Programmable Biology Under Constraint.
The real biotech story is not that biology has become easy to rewrite. It is that design power is rising faster than delivery, scale, and governance can comfortably absorb.
Personalized Gene Editing for One Baby Is a Breakthrough—And a Stress Test for Medicine
A baby’s personalized CRISPR treatment shows what precision medicine can become. It also exposes the manufacturing, regulatory, and access problems medicine has not solved yet.
AlphaGenome: Why AI DNA Models Matter Only If They Survive Biological Reality
AlphaGenome is impressive, but the real bottleneck in AI genomics is still biological validation, not model ambition.